Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 148.0% in January

Century Therapeutics, Inc. (NASDAQ:IPSC) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 807,117 shares, a growth of 148.0% from the December 31st total of 325,386 shares. Based on an average daily trading volume, of 3,991,795 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.0% of the shares of the stock are short sold. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,991,795 shares, the days-to-cover ratio is currently 0.2 days.

Insider Buying and Selling

In other Century Therapeutics news, CEO Brent Pfeiffenberger acquired 52,000 shares of the stock in a transaction dated Friday, December 12th. The shares were bought at an average price of $0.58 per share, with a total value of $30,160.00. Following the purchase, the chief executive officer directly owned 3,322,990 shares of the company’s stock, valued at approximately $1,927,334.20. This trade represents a 1.59% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chad Cowan bought 58,060 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average cost of $0.85 per share, with a total value of $49,351.00. Following the completion of the purchase, the insider owned 1,045,087 shares of the company’s stock, valued at approximately $888,323.95. The trade was a 5.88% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 145,060 shares of company stock valued at $97,011 and sold 65,987 shares valued at $29,798. Corporate insiders own 4.37% of the company’s stock.

Institutional Trading of Century Therapeutics

Several institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. acquired a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $25,000. Qube Research & Technologies Ltd acquired a new stake in shares of Century Therapeutics in the 2nd quarter valued at $38,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Century Therapeutics in the 2nd quarter worth about $50,000. Raymond James Financial Inc. bought a new position in Century Therapeutics in the second quarter valued at about $51,000. Finally, AQR Capital Management LLC increased its position in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the period. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Zacks Research upgraded shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Piper Sandler boosted their price target on shares of Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Leerink Partners lowered Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Finally, Wall Street Zen upgraded Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.80.

Century Therapeutics Trading Down 5.5%

Century Therapeutics stock traded down $0.11 during trading hours on Friday, reaching $1.90. 1,477,738 shares of the company were exchanged, compared to its average volume of 2,897,875. Century Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.71. The stock has a 50-day moving average of $1.23 and a 200 day moving average of $0.78. The firm has a market cap of $166.06 million, a price-to-earnings ratio of -5.94 and a beta of 1.72.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. As a group, research analysts forecast that Century Therapeutics will post -1.61 EPS for the current year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.